Automation leadership Beckman Coulter Diagnostics is expanding automated diagnostic capabilities, evidenced by the launch of a fully automated urinalysis system to handle rising testing volumes, presenting a sales opportunity for scalable automation solutions and related lab integration.

Neurodegenerative focus Strategic partnerships and product launches around p-Tau217 and extracellular vesicle–enabled immunoassays indicate a strong push into neurodegenerative disease testing, offering avenues to cross-sell advanced biomarker assays and RUO/IVD workflow integrations.

CE/IVDR momentum Recent CE marking and EU regulatory activity for p-Tau217 products, plus RUO offerings, create market access advantages and multi-region selling points for distributors and regional sales teams targeting Europe and CE-recognizing markets.

Clinical informatics The company emphasizes insightful clinical informatics and lab performance services, suggesting upsell opportunities in data analytics platforms, decision-support tools, and consulting services to optimize lab throughput and diagnostic yield.

Strategic partnerships Collaborations with NanoSomiX and ongoing alliances signal openness to co-developed solutions, enabling joint go-to-market strategies for novel biomarkers and EV-enabled assays across neurodegenerative indications, expanding reach in hospital and reference laboratory segments.